ArticleBiology direct2026
CHFR drives gastric cancer stemness and hepatic metastasis by suppressing ITCH-mediated ubiquitination and degradation of OCT4.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastric cancer (GC) is one of the most lethal malignancies worldwide, and hepatic metastasis is a major cause of its poor clinical prognosis. The stemness regulator octamer-binding transcription factor 4 (OCT4) drives the migration, invasion and metastasis of GC cells. As a RING-type E3 ubiquitin ligase, Checkpoint with Forkhead-associated and RING finger domains (CHFR) has been identified as a key promoter of metastasis in advanced GC. However, the precise molecular mechanisms underlying CHFR-mediated modulation of GC metastasis remain unclear.
resultsThis study systematically explored the biological functions and molecular mechanism of CHFR in GC via public data analysis, in vitro cell experiments and in vivo hepatic metastasis models. Functional assays revealed that CHFR overexpression enhanced the stemness and metastatic capacity of GC cells but inhibited cell proliferation. Mechanistically, CHFR stabilized OCT4 protein by blocking itchy E3 ubiquitin-protein ligase (ITCH)-mediated ubiquitination and proteasomal degradation of OCT4. Molecular docking predicted a direct interaction between CHFR and ITCH, and site mutation studies showed that their binding interface was essential for CHFR-induced OCT4 stabilization. DynaMut2 and FoldX mutagenesis confirmed Tyr530 (CHFR) and Thr222 (ITCH) as critical interfacial residues, whose alanine substitution weakened complex binding. Biochemical Co-IP ubiquitination assays verified CHFR targets ITCH for proteasomal degradation to suppress ITCH-dependent OCT4 breakdown. OCT4 knockdown rescue experiments further validated OCT4 as the essential downstream mediator of CHFR-induced glycolytic reprogramming, stemness and invasion in GC cells. Importantly, in vivo xenograft assays demonstrated that CHFR overexpression significantly promoted GC liver metastasis, whereas simultaneous overexpression of CHFR and ITCH reversed this metastatic phenotype.
conclusionCHFR enhances the stemness and metastatic progression of advanced GC cells by antagonizing ITCH-dependent OCT4 degradation, highlighting the CHFR/ITCH/OCT4 axis as a therapeutic target for GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.